Boston Scientific Corp.’s Michael Mahoney, who took the helm yesterday as chief executive officer, says innovation and smooth integration of recent acquisitions will return the company to growth next year.
Boston Scientific Corp. won’t begin a study of its hypertension treatment until it can analyze a failed effort by Medtronic Inc. and review its approach with U.S. regulators, Chief Executive Officer Michael Mahoney said.
Boston Scientific Corp.’s Watchman improved survival in patients with erratic heart rates after four years, an unexpected finding that may help create a $500 million market, said Chief Executive Officer Michael Mahoney.
MetroPCS Communications Inc., the wireless carrier looking to expand, may struggle to become a viable replacement for T-Mobile USA as AT&T Inc. tries to win government approval to buy the company from Deutsche Telekom AG.
Institutional Shareholder Services Inc., an investor advisory firm, recommended against T-Mobile USA Inc.’s merger with MetroPCS Communications Inc., dealing a blow to a transaction that lacks the support of MetroPCS’s biggest owner.
Boston Scientific Corp., the second- biggest maker of heart devices, plans to cut as many as 1,000 jobs in an expansion of its restructuring program that will save an additional $100 million to $115 million a year.